If you have been reading about LC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability studies show that NAD+ can hydrolyze under prolonged heat, extreme pH, or microbial contamination. Phosphate buffers near neutral pH are often used for short-term handling, though exact stability depends on concentration, temperature, and matrix. In biological samples, endogenous enzymes can rapidly degrade NAD+, making cold chain and fast processing important. Analytical reports should state extraction conditions, internal standards, and validation parameters. Without those details, comparisons across studies remain difficult and potentially misleading.
Laboratory measurement of NAD+ often begins with rapid quenching of cell or tissue samples to prevent enzymatic conversion. Acidic or alkaline extraction can precipitate proteins, but the chosen method affects recovery of oxidized and reduced forms. Enzymatic cycling assays provide high sensitivity by amplifying a NAD+-dependent reaction. High-performance liquid chromatography and mass spectrometry offer separation and structural confirmation. Each method has trade-offs in throughput, specificity, and the ability to distinguish NAD+ from close analogues.
Purified NAD+ is typically supplied as a white to off-white powder and stored desiccated at low temperature. Airtight containers limit moisture uptake, while protection from light reduces degradation of the nicotinamide ring. Aqueous stock solutions are less stable than solid material and are often aliquoted before freezing. Repeated freeze-thaw cycles can lower integrity, so working portions are kept separate. Purity is commonly checked by ultraviolet absorbance near 260 nm, high-performance liquid chromatography, or mass spectrometry.
Stability of NAD+ depends on form, temperature, pH, and water content. The solid is generally more stable than solutions, and it should be kept dry and cold. In solution, hydrolysis can cleave the dinucleotide, especially under alkaline conditions or at elevated temperature. Light exposure may also contribute to degradation. Buffers, chelating agents, and sterile handling can reduce losses, but no single condition preserves all preparations indefinitely. Researchers often prepare working solutions shortly before use and verify activity or purity after storage.
Quality control for NAD+ relies on identity, purity, and functional tests. A certificate of analysis may report high-performance liquid chromatography purity, ultraviolet spectrum, water content, and residual solvents. Because NAD+ is hygroscopic, gravimetric values can shift as material absorbs water, so purity should be interpreted alongside storage history. Mass spectrometry confirms molecular identity, while enzymatic assays show whether the material supports dehydrogenase activity. Commercial material is available as the free acid and as salts, and the counterion affects molecular weight, solubility, and how concentrations are calculated.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or precipitated solid |
| Solubility | Water-soluble | Also soluble in aqueous buffers; limited in nonpolar solvents |
| Typical storage | -20 °C, desiccated | Short-term solutions may be kept at 2-8 °C |
| Common analytical method | HPLC with UV detection | LC-MS provides additional confirmation |
| Stability risk | Hydrolysis | Accelerated by heat, extreme pH, and repeated freeze-thaw |
Quality control for NAD+ materials typically combines identity, purity, and water content checks. Identity may be confirmed by ultraviolet spectrum, retention time in chromatography, or mass accuracy, while purity is assessed by HPLC peak area or quantitative nuclear magnetic resonance. Residual water and solvents can affect molar calculations and enzyme assays, so Karl Fischer titration or thermogravimetric analysis may be used. Commercial materials vary in grade and counterion form, and published methods should specify the exact salt or hydrate when reporting concentrations. Regulatory status depends on intended use, with research reagents, dietary ingredients, and clinical products treated under different frameworks.
Quantification of NAD+ in biological samples usually relies on separation techniques coupled to sensitive detection. High-performance liquid chromatography with ultraviolet detection can measure the oxidized form by its absorbance near 260 nm, while mass spectrometry provides greater specificity and can distinguish NAD+ from close analogs. Enzymatic cycling assays use coupled dehydrogenase reactions to amplify signal and estimate NAD+ concentrations in cell or tissue extracts. Because NAD+ and NADH interconvert rapidly, sample preparation must quench metabolism quickly and preserve the redox state before analysis.
Solid NAD+ is relatively stable when kept dry, cold, and protected from light. Aqueous solutions are more vulnerable to hydrolysis and can lose activity during repeated freeze-thaw cycles or prolonged storage at ambient temperature. Stability depends on pH, ionic strength, and the presence of degrading enzymes or metal ions. For many laboratory uses, aliquots are stored frozen and thawed only once. Exact degradation rates vary by matrix, so stability should be checked for each application rather than assumed.
Laboratory handling of NAD+ follows standard practices for hygroscopic fine chemicals. Personnel typically avoid inhalation and skin contact, use gloves and eye protection, and work in a ventilated area. Quality control may include ultraviolet absorbance at the nicotinamide maximum, chromatographic purity, water content, and identity confirmation by mass spectrometry. Because commercial preparations can contain counterions, residual solvents, or related nucleotides, a certificate of analysis helps verify the material. Researchers should confirm that the form supplied matches the intended assay.
== Prognosis == Individuals with BED often have a lower overall quality of life and face social difficulties. Early behavior changes can predict a full recovery for the future. Individuals who have BED commonly have other conditions such as depression, personality disorder, bipolar disorder, substance abuse, body dysmorphic disorder, kleptomania, irritable bowel syndrome, fibromyalgia, or an anxiety disorder. They may also have history of attempted suicide and reoccurring panic attacks. While people of a normal weight may overeat occasionally, an ongoing habit of consuming large amounts of food in a short period of time may ultimately lead to weight gain and obesity. The main physical health consequences of this type of eating disorder are brought on by the weight gain resulting from calorie-laden bingeing episodes. Mental and emotional consequences of binge eating disorder include social weight stigma and emotional loss of control. Up to 70% of individuals with BED may also be obese, and therefore obesity-associated morbidities such as high blood pressure and coronary artery disease, type 2 diabetes mellitus, gastrointestinal issues (e.g., gallbladder disease), high cholesterol levels, musculoskeletal problems and obstructive sleep apnea may also be present. One study found a 42% obesity rate in those who have received a BED diagnosis. Additionally, a higher morbid obesity prevalence was observed in this population compared to a population without eating disorders.
== Column adsorption equilibrium == For an adsorption column, the column resin (the stationary phase) is composed of microbeads. Even smaller particles such as proteins, carbohydrates, metal ions, or other chemical compounds are conjugated onto the microbeads. Each binding particle that is attached to the microbead can be assumed to bind in a 1:1 ratio with the solute sample sent through the column that needs to be purified or separated. Binding between the target molecule to be separated and the binding molecule on the column beads can be modeled using a simple equilibrium reaction Keq = [CS]/([C][S]) where Keq is the equilibrium constant, [C] and [S] are the concentrations of the target molecule and the binding molecule on the column resin, respectively. [CS] is the concentration of the complex of the target molecule bound to the column resin. Using this as a basis, three different isotherms can be used to describe the binding dynamics of a column chromatography: linear, Langmuir, and Freundlich. The linear isotherm occurs when the solute concentration needed to be purified is very small relative to the binding molecule. Thus, the equilibrium can be defined as:
== Background == The first successful delivery of a drug across the BBB occurred in 1995. The drug used was hexapeptide dalargin, an anti-nociceptive peptide that cannot cross the BBB alone. It was encapsulated in polysorbate 80 coated nanoparticles and intravenously injected. This was a huge breakthrough in the nanoparticle drug delivery field, and it helped advance research and development toward clinical trials of nanoparticle delivery systems. Nanoparticles range in size from 10 - 1000 nm (or 1 μm) and they can be made from natural or artificial polymers, lipids, dendrimers, and micelles. Most polymers used for nanoparticle drug delivery systems are natural, biocompatible, and biodegradable, which helps prevent contamination in the CNS. Several current methods for drug delivery to the brain include the use of liposomes, prodrugs, and carrier-mediated transporters. Many different delivery methods exist to transport these drugs into the body, such as peroral, intranasal, intravenous, and intracranial. For nanoparticles, most studies have shown increasing progression with intravenous delivery. Along with delivery and transport methods, there are several means of functionalizing, or activating, the nanoparticle carriers. These means include dissolving or absorbing a drug throughout the nanoparticle, encapsulating a drug inside the particle, or attaching a drug on the surface of the particle.
For mass spectrometry analyses of a macromolecule, such as a protein, the analyte must be ionized and vaporized by laser irradiation. The problem is that the direct irradiation of an intense laser pulse on a macromolecule causes cleavage of the analyte into tiny fragments and the loss of its structure. In February 1985, Tanaka found that by using a mixture of ultra fine metal powder in glycerol as a matrix, an analyte can be ionized without losing its structure. His work was filed as a patent application in 1985, and after the patent application was made public reported at the Annual Conference of the Mass Spectrometry Society of Japan held in Kyoto, in May 1987 and became known as soft laser desorption (SLD). The obscure Tanaka had been at the second-lowest rank at Shimadzu when he won the Nobel Prize. The embarrassed company immediately promoted Tanaka to research fellow, and named a laboratory after him. However, there was some criticism about his winning the prize, saying that contribution by two German scientists, Franz Hillenkamp and Michael Karas was also big enough not to be dismissed, and therefore they should also be included as prize winners. This is because they first reported in 1985 a method, with higher sensitivity using a small organic compound as a matrix, that they named matrix-assisted laser desorption/ionization (MALDI). Also Tanaka's SLD is not used currently for biomolecules analysis, meanwhile MALDI is widely used in mass spectrometry research laboratories.
Sources: en.wikipedia.org
=== June === 6 June MPs vote to suspend Margaret Ferrier, the MP for Rutherglen and Hamilton West, from the House of Commons for 30 days for breaching COVID-19 regulations, almost certainly triggering a by-election in her constituency. Kevin Stewart resigns as Minister for Transport after experiencing poor mental health. 7 June – Circular Economy Minister Lorna Slater confirms that Scotland's Deposit Return Scheme is to be delayed until at least October 2025, meaning it will launch at a similar time to similar projects in other parts of the UK. 8 June – Members of the National Union of Rail, Maritime and Transport Workers at ScotRail vote to accept a 5% pay increase for 2023–24. 11 June – Police Scotland arrest former First Minister Nicola Sturgeon as part of their ongoing investigation into the SNP's finances. She is subsequently released without charge. 12 June – First Minister Humza Yousaf tells BBC News he will not suspend Nicola Sturgeon from the SNP following her arrest. 13 June BMA Scotland announces that junior doctors have rejected a 14.5% pay offer from the Scottish Government and will stage a 72-hour strike from 12 to 15 July. Màiri McAllan, Scotland's Cabinet Secretary for Net Zero and Just Transition, is additionally appointed as Minister for Transport, replacing Kevin Stewart in the role. 14 June – Jo Farrell, the current Chief Constable of Durham Constabulary, is appointed as Police Scotland's first female Chief Constable; she will replace Sir Iain Livingstone, who retires in August.
Paramagnetic Fluorescence Quenching, the allowance of new electronic states upon binding a paramagnetic metal atom Photoinduced Electron Transfer (PET), the blocking of a lower energy state due to the binding of a metal atom. Photoinduced Charge Transfer (PCT), the modulation of energy levels in a complex by charge transfer within a conjugated pi system. Fluorescence Resonance Energy Transfer (FRET), the transfer of an exciton from a donor to an acceptor, modulating the emission spectrum. Excimer/Exciplex formation, the formation of a state that is a hybrid of the ground and excited states. This has novel fluorescent properties. Chemodosimeters, complexes that undergo irreversible reactions with other species upon binding a metal to form new compounds with novel fluorescent spectra. Fluorophores are essential to some measurement of the metal binding event, and indirectly, metal concentration. There are many types, all with different properties that make them advantageous for different applications. Some work as small metal sensors completely on their own while others must be complexed with a subunit that can chelate or bind a metal ion. Rhodamine for example undergoes a conformation change upon the binding of a metal ion. In so doing it switches between a colorless, non-fluorescent spirocyclic form to a fluorescent, pink open cyclic form. Quinoline based sensors have been developed that form luminescent complexes with Cd(II) and fluorescent ones with Zn(II).
=== In adults === While there are some similarities between adults and children, OSA does not have the same consequences in both populations. Examples of similarities are the snoring – which is the most common complaint in both pediatric OSA and OSA in adults – variability of blood pressure and cardiovascular morbidities. A major difference is the excessive daytime sleepiness (EDS) which is commonly reported in adult OSA, while it is not very common in pediatric OSA. Nevertheless, OSA in adults also implies a large scope of adverse and serious consequences, the latter leading to higher mortality amongst OSA patients. Those consequences are even worsened by common morbidities such as obesity.
== History == The predecessor of LGD-4033, LG121071 (LGD-121071), was discovered by Ligand Pharmaceuticals and was first described in the literature in January 1999. It was the first orally active nonsteroidal androgen receptor agonist to be discovered. LG121071 is a tricyclic quinoline derivative, and is structurally distinct from arylpropionamide SARMs like andarine and enobosarm (ostarine). LGD-2226, a bicyclic quinoline SARM, was subsequently developed by Ligand Pharmaceuticals and TAP Pharmaceuticals in 2001. Other quinoline SARMs, like LGD-2941 and LGD-3303, were also subsequently developed by Ligand Pharmaceuticals prior to the development of LGD-4033. LGD-4033 was developed by Ligand Pharmaceuticals and was first described in the literature in 2010. On the basis of a favorable preclinical profile, phase 1 clinical trials of LGD-4033 began in 2009. The results of a single-dose phase 1 clinical trial were published as a conference abstract in 2010 and the findings of a multi-dose phase 1 trial were published as a journal article in 2013. A third phase 1 trial was also conducted. By 2012, a phase 2 trial of LGD-4033 for the treatment of muscle wasting related to cancer cachexia, acute rehabilitation (e.g., hip fracture), and acute illness was being prepared by Ligand Pharmaceuticals. On 22 May 2014, Viking Therapeutics licensed the developmental rights of LGD-4033 from Ligand Pharmaceuticals and intended to advance the compound into mid-to-late-stage clinical trials.
=== Extracellular matrix === Extracellular matrix materials are commercially available and are used in reconstructive surgery, treatment of chronic wounds, and some orthopedic surgeries; as of January 2017 clinical studies were under way to use them in heart surgery to try to repair damaged heart tissue. The use of fish skin with its natural constituent of omega 3, has been developed by an Icelandic company Kereceis. Omega 3 is a natural anti-inflammatory, and the fish skin material acts as a scaffold for cell regeneration. In 2016 their product Omega3 Wound was approved by the FDA for the treatment of chronic wounds and burns. In 2021 the FDA gave approval for Omega3 Surgibind to be used in surgical applications including plastic surgery.
Sources: en.wikipedia.org
Another less insidious tactic journals employ is to publish a large portion of its papers, or at least the papers expected to be highly cited, early in the calendar year. This gives those papers more time to gather citations. Several methods, not necessarily with nefarious intent, exist for a journal to cite articles in the same journal which will increase the journal's impact factor. Beyond editorial policies that may skew the impact factor, journals can take overt steps to game the system. For example, in 2007, the specialist journal Folia Phoniatrica et Logopaedica, with an impact factor of 0.66, published an editorial that cited all its articles from 2005 to 2006 in a protest against the "absurd scientific situation in some countries" related to use of the impact factor. The large number of citations meant that the impact factor for that journal increased to 1.44. As a result of the increase, the journal was not included in the 2008 and 2009 Journal Citation Reports. Coercive citation is a practice in which an editor forces an author to add extraneous citations to an article before the journal will agree to publish it, in order to inflate the journal's impact factor. A survey published in 2012 indicates that coercive citation has been experienced by one in five researchers working in economics, sociology, psychology, and multiple business disciplines, and it is more common in business and in journals with a lower impact factor. Editors of leading business journals banded together to disavow the practice.
The duration of estradiol esters in oil solution by intramuscular injection is dose-dependent. With estradiol valerate, it is reported that a dose of 5 mg has a duration of 7 to 8 days, 10 mg a duration of 10 to 14 days, 40 mg a duration of 2 to 3 weeks, and 100 mg a duration of 3 to 4 weeks. High doses of estradiol valerate, such as 40 mg per week, can achieve pregnancy levels of estradiol. A study of pseudopregnancy with intramuscular injections of 40 mg/week estradiol valerate and 250 mg/week hydroxyprogesterone caproate observed estradiol levels of about 2,500 to 3,000 pg/mL.
=== Turkey and tryptophan === A common myth holds that turkey is especially high in tryptophan, resulting in sleepiness after it is consumed, as may occur at the traditional meal of the North American holiday of Thanksgiving. However, the tryptophan content of turkey is comparable to chicken, beef, and other meats, and does not result in higher blood tryptophan levels than other common foods. Certain foods, such as soybeans, sesame and sunflower seeds, and certain cheeses, are also high in tryptophan. Whether it is possible or not that these may induce sleepiness if consumed in sufficient quantities has yet to be studied.
== Epidemiology == In a study in British Columbia, the overall incidence of the inborn errors of metabolism were estimated to be 40 per 100,000 live births or 1 in 2,500 births, overall representing more than approximately 15% of single gene disorders in the population. While a Mexican study established an overall incidence of 3.4:1,000 live newborns and a carrier detection of 6.8:1,000 NBS.
Sources: en.wikipedia.org
Many enzymes consume or produce NAD+ within seconds after a sample is collected. Quenching stops those reactions and helps preserve the ratio between oxidized and reduced forms. The exact quenching method depends on the tissue or cell type and the analytes of interest.
NAD+ is present in blood cells, but plasma measurements are complicated by release from cells during processing. Careful collection and immediate separation of cellular components are required. Researchers often prefer specific cell or tissue samples to answer questions about NAD+ pools.
Solid NAD+ is dissolved in suitable aqueous buffer, often near neutral pH, and kept cold. Solutions are typically aliquoted to avoid repeated freeze-thaw cycles. Protection from light and microbial contamination supports stability during storage.
Common methods include enzymatic cycling assays, HPLC with UV detection, and LC-MS. The choice depends on sample size, specificity needs, and available equipment. Rapid quenching before analysis is important because NAD+ and NADH can interconvert.